PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a US Patent titled “Compositions and Methods for Treatment of Cervical Cancer.” This patent specifically protects the use of the Advaxis HPV construct for the treatment of late stage cervical cancer, an unmet medical need for which this agent is currently being evaluated in 2 Phase II clinical trials, two of which are in recurrent metastatic cervical cancer, one in India and one in collaboration with the Gynecologic Oncology Group of the National Cancer Institute in the US.
